Overview

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Status:
Active, not recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

This research study is studying a targeted therapy drug as a possible treatment for IDH2 mutant acute myeloid leukemia or chronic myelomonocytic leukemia while undergoing hematopoietic stem cell transplantation. The drug involved in this study is: -Enasidenib.

Phase:

Phase 1

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Celgene